Selected data models

You must log in to select data models for download or further analysis.

67 Search results.
Relevance Rating New first Old first

Eligibility Chronic Lymphocytic Leukemia NCT00381004

- 2/8/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00381004

Eligibility Chronic Lymphocytic Leukemia NCT00413478

- 2/8/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00413478

Eligibility Chronic Lymphocytic Leukemia NCT00290004

- 2/7/17 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290004

Eligibility Chronic Lymphocytic Leukemia NCT00267059

- 2/7/17 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00267059

Eligibility Chronic Lymphocytic Leukemia NCT00254410

- 2/6/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years; ODM derived from: https://clinicaltrials.gov/show/NCT00254410

Eligibility Chronic Lymphocytic Leukaemia Refractory NCT00366418

- 2/6/17 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00366418

Eligibility Leukemia NCT00323557

- 10/6/16 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00323557

Eligibility Chronic Lymphocytic Leukemia NCT00931645

- 5/1/16 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00931645

Eligibility Chronic Lymphocytic Leukemia NCT01423032

- 5/1/16 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01423032

Eligibility Leukemia, Lymphocytic, Chronic, B-Cell NCT00220311

- 4/15/16 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia; ODM derived from: https://clinicaltrials.gov/show/NCT00220311

Eligibility Chronic Lymphocytic Leukemia NCT00022880

- 3/20/16 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00022880

Follow up EBMT CLL

- 3/13/16 - 1 form, 19 itemgroups, 148 items, 1 language
Itemgroups: Follow Up, Patient last seen, Acute Graft versus Host Disease (aGvHD) since last report, Chronic Graft versus Host Disease (cGvHD) since last report, Other Complications since last report, Other complications since last report - Graft Assessment and Haemopoietic chimaerism, Other complications since last report - Graft Assessment and Haemopoietic chimaerism - Specific tests, Other complications since last report - secondary malignancy, lymphoproliferative or myeloproliferative disorder diagnosed, Additional therapies since last follow up, Additional Therapies - Cellular Therapy, Additional Therapies - Disease treatment, First evidence of relapse or progression since last HSCT, Last Disease status, Last Disease status - Residual Disease Status, Last Disease status - Conception, Last Disease status - Survival status, Last Disease status - Cause of death (if dead), Additional notes if applicable, Identification and Signature
ODM derived from HSCT forms on http://www.ebmt.org/

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial